Skip to content
AgingNexus
☰ Menu

Evidence brief · intervention

Senolytics

Synthesized from 10 indexed sources · 2026-07-26 MST · preview (no AI key)
Preview synthesis (deterministic, no AI key configured). Set a provider key to generate the full brief.

Synthesis (preview — no live AI key for the active provider):

Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].

Set the active provider's API key to generate full model-written analysis.

Sources

  1. [1] The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
  2. [2] Senolytics improve physical function and increase lifespan in old age
  3. [3] Toxicity of lead: a review with recent updates
  4. [4] Cellular senescence mediates fibrotic pulmonary disease
  5. [5] Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
  6. [6] Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
  7. [7] Senolytic drugs: from discovery to translation
  8. [8] Senescence and the SASP: many therapeutic avenues
  9. [9] Bioactive compounds and healthy aging: search for new nutraceutical compounds through the experimental model of chronological aging in yeast
  10. [10] Dasatinib and quercetin prevent alveolar bone loss in aged mice
All Senolytics works → Intervention dossier →